Literature DB >> 22298801

Chemotherapy and fingerprint loss: beyond cosmetic.

Mahmoud S Al-Ahwal1.   

Abstract

Hand-foot syndrome (HFS) is a common adverse reaction to several chemotherapy drugs. Focus has been on the clinically relevant sequelae associated with this condition, with fingerprint loss receiving little attention. We report the case of a 53-year old male patient with terminal metastatic adenocarcinoma of the rectum involving the liver and lungs who developed grade 3 HFS while on capecitabine therapy. This resulted in his inability to process required government papers as a result of the loss of his fingerprints, imposing significant inconvenience and frustration on a person severely challenged by his deteriorating health. We believe clinicians should pay more attention to this possible outcome that can add additional stress in the lives of patients whose quality of life is already severely compromised.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298801      PMCID: PMC3286180          DOI: 10.1634/theoncologist.2011-0243

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  7 in total

1.  Travel warning with capecitabine.

Authors:  M Wong; S-P Choo; E-H Tan
Journal:  Ann Oncol       Date:  2009-05-26       Impact factor: 32.976

Review 2.  Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

Authors:  Roger Anderson; Aminah Jatoi; Caroline Robert; Laura S Wood; Karen N Keating; Mario E Lacouture
Journal:  Oncologist       Date:  2009-03-10

3.  Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.

Authors:  Nobuyasu Yoshimoto; Toshinari Yamashita; Takashi Fujita; Hironori Hayashi; Nobuyuki Tsunoda; Mariko Kimura; Norimasa Tsuzuki; Hiroko Yamashita; Tatsuya Toyama; Naoto Kondo; Hiroji Iwata
Journal:  Breast Cancer       Date:  2009-09-30       Impact factor: 4.239

Review 4.  Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

Authors:  Yvonne Lassere; Paulo Hoff
Journal:  Eur J Oncol Nurs       Date:  2004       Impact factor: 2.398

5.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Authors:  M E Lacouture; L M Reilly; P Gerami; J Guitart
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976

6.  Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.

Authors:  Katherina Podlekareva Farr; Akmal Safwat
Journal:  Case Rep Oncol       Date:  2011-04-11

7.  Hand-foot syndrome due to capecitabine.

Authors:  Amar Surjushe; Resham Vasani; Sudhir Medhekar; Minal Thakre; D G Saple
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

  7 in total
  4 in total

1.  Fingerprint changes among cancer patients treated with paclitaxel.

Authors:  Payam Azadeh; Simin Dashti-Khavidaki; Ali Yaghobi Joybari; Samaneh Sarbaz; Atefeh Jafari; Mehdi Yaseri; Afshin Amini; Maryam Farasatinasab
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-17       Impact factor: 4.553

2.  Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine.

Authors:  Philip R Cohen
Journal:  Cureus       Date:  2017-01-09

Review 3.  Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.

Authors:  Jian Zhao; Xia Zhang; Xiaonan Cui; Di Wang; Bin Zhang; Liying Ban
Journal:  Oncol Res       Date:  2019-09-26       Impact factor: 5.574

Review 4.  Dermatologic conditions in women receiving systemic cancer therapy.

Authors:  Michelle N Ferreira; Julie Y Ramseier; Jonathan S Leventhal
Journal:  Int J Womens Dermatol       Date:  2019-11-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.